Clinical Trials Logo

Solid Tumor, Adult clinical trials

View clinical trials related to Solid Tumor, Adult.

Filter by:

NCT ID: NCT06326411 Not yet recruiting - Melanoma Clinical Trials

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

NST-628
Start date: March 2024
Phase: Phase 1
Study type: Interventional

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

NCT ID: NCT06292845 Not yet recruiting - Solid Tumor, Adult Clinical Trials

Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents

SprayDye
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This is a proof-of-principle study, that uses freshly resected human solid tumor specimens to assess the performance of topically applied fluorescent imaging agents for the detection of tumor tissue and close / tumor-positive resection margins ex vivo. Surgery will be performed in conformity with hospital protocol. The study will not interfere with the standard clinical care.

NCT ID: NCT06270082 Recruiting - Colorectal Cancer Clinical Trials

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Start date: December 18, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.

NCT ID: NCT06265727 Recruiting - Solid Tumor, Adult Clinical Trials

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Start date: March 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701 when used alone? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701 on its own. They will have blood tests and other assessments to measure whether CRB-701 will have CT or MRI scans to measure the effect on tumors.

NCT ID: NCT06265688 Not yet recruiting - Solid Tumor, Adult Clinical Trials

First In Human Study of CX-2051 in Advanced Solid Tumors

Start date: March 31, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 in adult subjects with advanced solid tumors.

NCT ID: NCT06264921 Not yet recruiting - Ovarian Cancer Clinical Trials

A Phase 1 Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Start date: February 2024
Phase: Phase 1
Study type: Interventional

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).

NCT ID: NCT06244771 Recruiting - Colorectal Cancer Clinical Trials

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

PROSPER
Start date: February 12, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

NCT ID: NCT06240767 Recruiting - Advanced Cancer Clinical Trials

Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils

Start date: November 1, 2023
Phase: Phase 1
Study type: Interventional

It is planned to recruit about 100 pathologically confirmed subjects with advanced solid tumors (non-small cell lung cancer, breast cancer, ovarian cancer, stomach cancer, colorectal cancer, pancreatic cancer, mesothelioma, etc.) that have progressed after standard second-line or above treatment such as surgery, chemoradiotherapy, targeted therapy and PD-1 antibody therapy. A single infusion of human granulocytes with anti-cancer mouse characteristics was performed for 5 consecutive transfusions at a interval of 2±1 day, and the safety and efficacy were clinically observed. After the investigator's judgment and discussion with the sponsor, more cycles of treatment can be received after the informed consent is completed until the criteria for stopping treatment are met.

NCT ID: NCT06232863 Recruiting - Solid Tumor, Adult Clinical Trials

A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer

Start date: January 18, 2023
Phase: Phase 1
Study type: Interventional

This study will assess the safety and tolerability and pharmacokinetics of BH009 in patients with advanced head and neck squamous (non-nasopharyngeal) and ovarian cancer.

NCT ID: NCT06228326 Recruiting - Clinical trials for Metastatic Colorectal Cancer

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Start date: February 2024
Phase: Phase 1
Study type: Interventional

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector that is designed to stimulate an anti-tumor immune response through the production of cytokines delivered to the airways of people with advanced solid tumor malignancies affecting the lungs via nebulization. This Phase 1, open-label, multicenter, dose escalation and expansion study is designed to evaluate the safety and tolerability of KB707 in adults with with advanced solid tumor malignancies affecting the lungs who have progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The study will include a dose escalation portion for single agent KB707 using a standard 3+3 design followed by an expansion portion to further evaluate single agent KB707 at a dose determined by preliminary data in the dose escalation phase. Subjects in both the dose escalation and dose expansion cohorts will receive KB707 via nebulization weekly for three weeks, then every three weeks for up to two years until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.